2,549 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Sivia Capital Partners LLC

Key Points

• Sivia Capital Partners LLC has acquired a new stake in Zimmer Biomet Holdings, Inc., purchasing 2,549 shares valued at approximately $232,000 during the second quarter.
• Several analysts have raised their price targets for Zimmer Biomet, with Stifel Nicolaus increasing it to $118.00 and Roth Capital reaffirming a "buy" rating.
• Zimmer Biomet announced a quarterly dividend of $0.24 per share, set to be paid on October 31st, representing an annualized yield of 1.0%.

Sivia Capital Partners LLC purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,549 shares of the medical equipment provider's stock, valued at approximately $232,000.

Other large investors have also recently bought and sold shares of the company. Ameriprise Financial Inc. increased its position in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock worth $517,039,000 after purchasing an additional 3,208,596 shares during the last quarter. JPMorgan Chase & Co. increased its position in Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider's stock worth $235,571,000 after purchasing an additional 1,488,918 shares during the last quarter. Nuveen LLC acquired a new position in Zimmer Biomet in the 1st quarter worth about $155,891,000. Alyeska Investment Group L.P. acquired a new position in Zimmer Biomet in the 1st quarter worth about $101,294,000. Finally, Boston Trust Walden Corp acquired a new position in Zimmer Biomet in the 1st quarter worth about $54,108,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 0.7%

Zimmer Biomet stock traded up $0.71 during mid-day trading on Tuesday, hitting $102.45. The company's stock had a trading volume of 256,583 shares, compared to its average volume of 1,974,426. The stock has a market cap of $20.29 billion, a price-to-earnings ratio of 24.94, a price-to-earnings-growth ratio of 2.30 and a beta of 0.68. The business has a 50 day moving average price of $100.22 and a 200-day moving average price of $99.31. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.22 and a 12 month high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The company had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.06 billion. During the same quarter in the previous year, the company earned $2.01 earnings per share. Zimmer Biomet's quarterly revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet's payout ratio is currently 23.36%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the business's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ZBH. Rothschild & Co Redburn started coverage on Zimmer Biomet in a report on Thursday, September 18th. They set a "buy" rating and a $130.00 price objective on the stock. Raymond James Financial raised their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Rothschild Redb raised Zimmer Biomet to a "strong-buy" rating in a report on Thursday, September 18th. Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a report on Tuesday, July 8th. Finally, Royal Bank Of Canada lifted their target price on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $113.16.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.